Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis

• Main Authors: Hauer L (Author), Moztarzadeh O (Author), Baghalipour N (Author), Gencur J (Author)
• Format: Book
• Published: Dove Medical Press, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2230-326X
• Keywords: plaque psoriasis; anti-interleukin 17-a; immunomodulator; interleukins inhibitors; mronj; Dermatology; RL1-803
• Source: Psoriasis: Targets and Therapy, Vol Volume 14, Pp 115-120 (2024)

Lukas Hauer,1 Omid Moztarzadeh,1,2 Nasimeh Baghalipour,1 Jiri Gencur1 1Department of Stomatology, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, 32300, Czech Republic; 2Department of Anatomy, Faculty of Medicine in Pilsen, Charles University, Pilsen, 32300, Czech RepublicCorrespondence: Omid Moztarzadeh, Department of Anatomy, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 32300, Czech Republic, Tel [phone], Email [e-mail]; [e-mail]: The use of antiangiogenic and antiresorptive medications, particularly in patients with cancer or osteoporosis, can lead to osteonecrosis of the jaw following tooth extraction, trauma or arising spontaneously- A condition known as medication-related osteonecrosis of the jaw (MRONJ). In this article, we present a unique case of MRONJ in a patient with no history of antiresorptive or antiangiogenic drug use, who was instead taking the anti-interleukin 17-A (Secukinumab) medication for severe psoriasis. This association has not been previously reported in the literature.Keywords: plaque psoriasis, anti-interleukin 17-A, immunomodulator, interleukins inhibitors, MRONJ